<DOC>
	<DOCNO>NCT00417482</DOCNO>
	<brief_summary>In patient Alzheimer 's disease ( AD ) respond antipsychotic treatment psychosis and/or agitation/aggression , relapse risk discontinuation establish . AD patient psychosis and/or agitation/aggression receive 16 week open risperidone treatment ( Phase A ) . Responders randomize , double-blind , one three arm Phase B : ( 1 ) continuation risperidone 32 week , ( 2 ) risperidone 16 week follow placebo 16 week , ( 3 ) placebo 32 week . The primary outcome time relapse psychosis/agitation .</brief_summary>
	<brief_title>Antipsychotic Discontinuation Alzheimer 's Disease</brief_title>
	<detailed_description>This multicenter study ( 6 academic site 2 non-academic site ) involve treat AD patient ( assist living nursing home patient , outpatient ) use atypical antipsychotic , risperidone . In Phase A , 180 AD patient psychosis and/or agitation/aggression receive open treatment risperidone 16 week . Responders randomize , double-blind , one three arm Phase B : ( 1 ) continuation risperidone next 32 week , ( 2 ) risperidone next 16 week follow placebo 16 week , ( 3 ) placebo next 32 week . The primary hypothesis first 16 week Phase B , relapse risk low continuation risperidone ( Arms 1 + 2 ) compare discontinuation placebo ( Arm 3 ) . The secondary hypothesis second 16 week Phase B , relapse risk low continuation risperidone ( Arm 1 ) compare discontinuation placebo ( Arm 2 ) . For randomized time period , proportion relapse compare interpretive support . This design provide useful data efficacy side effect long term treatment risperidone , , particular , critical information time relapse likelihood relapse patient switch risperidone placebo . This information essential guide clinician toward optimal use medication one challenge type patient : AD patient psychosis and/or agitation/aggression . The result study also help address Federal regulation urge early antipsychotic discontinuation nursing home .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Dementia , either sex , age 5095 year Probable Alzheimer 's disease Intellectual impairment present least 6 month Mini Mental State Exam ( MMSE ) score 526 outpatient 226 nursing home patient Availability informant direct contact patient average least every week 3 month prior study entry Meets Neuropsychiatric Inventory ( NPI ) criterion either ( 1 ) psychosis , ( 2 ) agitation/aggression Able mobilize independently ( wheelchairbound , patient must able selfpropel ) Free psychotropic medication ( able tolerate washout ) least 1 week prior study entry . Low dose antidepressant sedative/hypnotics allow wash dose remain stable study duration Expected complete study ( include efficacy evaluation ) without major sensory impairment would prevent participation aspect study Current primary Axis I psychiatric disorder AD Substance abuse dependence currently , within past year Dementia due head trauma History allergy risperidone intolerance risperidone Diffuse Lewy body disease History seizure disorder , infectious encephalitis , Parkinson 's disease , central nervous system ( CNS ) neoplasm , tardive dyskinesia , stroke , transient ischemic attack ( TIA ) uncontrolled atrial fibrillation Use monoamine oxidase inhibitor ( MAOIs ) unable undergo 3week washout ; patient also may take MAOIs 2 week complete study In treatment ( ) depot antipsychotic within 2 week screen visit Untreated incompletely treated hypothyroidism Active , unstable medical condition require active medication adjustment surgery Need electroconvulsive treatment ( ECT ) Significant risk harm others result randomization placebo History malignant neoplasm last 5 year</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Risperidone treatment , psychosis , agitation , aggression ,</keyword>
	<keyword>discontinuation , placebo</keyword>
</DOC>